FSTL3 expression was enriched in the liver of NAFLD patients with significant and advanced fibrosis, and serum FSTL3 partially mediated the association of increased liver fibrosis risk with AMI in T2DM patients. The gene discussed is FSTL3; the disease is metabolic dysfunction-associated steatotic liver disease.